112 Chapter 7 References [1] Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, et al. Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 2020;38:1569–79. https://doi.org/10.1200/JCO.19.02503. [2] Wang X, Palaskas NL, Yusuf SW, Abe J, Lopez-Mattei J, Banchs J, et al. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J Thorac Oncol 2020. https:// doi.org/10.1016/j.jtho.2020.06.014. [3] Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, et al. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 2019;141:33–40. https://doi.org/10.1016/j.radonc.2019.09.015. [4] Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer. J Thorac Oncol 2017;12:293–301. https://doi.org/10.1016/j.jtho.2016.09.134. [5] Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer. J Am Coll Cardiol 2019;73:2976–87. https://doi.org/10.1016/j.jacc.2019.03.500. [6] Song EY, Venkat P, Fradley M, Frakes JM, Klocksieben F, Fontaine J, et al. Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery 2020;11:68–75. https://doi.org/10.21037/jgo.2019.12.05. [7] Beukema JC, de Groot C, Plukker JTM, Vliegenthart R, Langendijk JA, van Luijk P, et al. Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: A prospective crosssectional pilot study. Radiother Oncol 2022;167:72–7. https://doi.org/10.1016/j.radonc.2021.11.029. [8] DeFilippi CR, De Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA - J Am Med Assoc 2010;304:2494–502. https:// doi.org/10.1001/jama.2010.1708. [9] Ndrepepa G, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A. High-sensitivity troponin T level and angiographic severity of coronary artery disease. Am J Cardiol 2011;108:639–43. https:// doi.org/10.1016/j.amjcard.2011.04.012. [10] Burkhart CS, Cuthbertson BH, Mbc HB, Gibson SC, Mahla E, Leibowitz DW, et al. The Predictive Ability of Pre-Operative B-Type Natriuretic Peptide in Vascular Patients for Major Adverse Cardiac Events An Individual Patient Data Meta-Analysis. JAC 2011;58:522–9. https://doi.org/10.1016/j. jacc.2011.04.018. [11] Rehman SU, Januzzi JL. Natriuretic Peptide Testing in Clinical Medicine. Cardiol Rev 2008;16:240– 9. https://doi.org/10.1097/CRD.0b013e3181815333. [12] Gaggin HK, Januzzi JL. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013;1832:2442–50. https://doi.org/10.1016/j.bbadis.2012.12.014. [13] Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the CardioOncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020;22:1966–83. https://doi.org/10.1002/ ejhf.2017. [14] Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 2020;22:350–61. https://doi.org/10.1002/ejhf.1631. [15] Jingu K, Nemoto K, Kaneta T, Fukada H, Takahashi S YS. Temporal change in brain natriuretic peptide after radiotherapy for thoracic esophageal cancer. Int J Radiat Oncol Biol Phys 2007;69:1417–23. https://doi.org/10.1016/j.ijrobp.2007.05.054. [16] Kozak KR, Hong TS, Sluss PM, Lewandrowski EL, Aleryani SL, Macdonald SM, et al. Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer 2008;62:351–5. https:// doi.org/10.1016/j.lungcan.2008.03.024.
RkJQdWJsaXNoZXIy MTk4NDMw